Why Is Amdocs (DOX) Up 1.3% Since Last Earnings Report?

11.12.25 17:30 Uhr

Werte in diesem Artikel
Aktien

67,72 EUR 0,44 EUR 0,65%

It has been about a month since the last earnings report for Amdocs (DOX). Shares have added about 1.3% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Amdocs due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Amdocs Limited before we dive into how investors and analysts have reacted as of late.Amdocs Q4 Earnings Surpass Expectations, Revenues Fall Y/YAmdocs reported better-than-expected fourth-quarter fiscal 2025 results. The company posted non-GAAP earnings of $1.83 per share, which came above the midpoint of the management’s guidance of $1.79-$1.85 and increased 7.6% year over year. The figure also exceeded the Zacks Consensus Estimate of $1.82.Amdocs’ fourth-quarter revenues of $1.15 billion surpassed the consensus mark of $1.14 billion. However, compared with the year-ago quarter, revenues were down 9% on a reported basis due to the phase-out of certain business activities. Excluding the effect of phase-out business activities, revenues were up 2.8% year over year in pro forma constant currency.Amdocs’ Q4 DetailsAmdocs reported a decline in revenues across North America, Europe and the Rest of the World (RoW). North America reported revenues of $762 million (66% of total revenues), which decreased 8.8% year over year. RoW revenues (18% of total revenues) dropped 5% year over year to $208 million.Europe revenues (16% of total revenues) of $180 million decreased 0.8% year over year. Our model estimates for North America, RoW and Europe were pinned at $743.4 million, $221.2 million and $176.7 million, respectively.Managed services revenues rose 3.7% year over year to $748.3 million. The company ended the fourth quarter of fiscal 2025 with a 12-month backlog of $4.19 billion, up $40 million sequentially. Our model estimates for managed services revenues and backlog were pegged at $731.5 million and $4.07 billion, respectively.The non-GAAP operating income increased 5% year over year to $248.1 million, while the operating margin expanded 290 basis points (bps) to 21.6%.Amdocs’ Balance Sheet & Cash FlowAmdocs had cash and short-term investments of $325 million as of Sept. 30, 2025 compared with $342.5 million as of June 30, 2025. Long-term debt was $646.9 million as of Sept. 30, 2025, almost flat to the June 30, 2025 level of $646.7 million.During the fourth quarter, it generated an operating cash flow of $229.8 million and a free cash flow of $198.6 million. In full fiscal 2025, it generated operating cash flow and free cash flow of $749.1 million and $645.1 million, respectively.Amdocs Initiates Guidance for Q1 & FY2026Amdocs initiated guidance for the first quarter and fiscal 2026. For the first quarter, the company expects revenues to be in the band of $1.135-$1.175 billion (midpoint $1.155 billion). Amdocs expects non-GAAP earnings per share to be between $1.73 and $1.79. The Zacks Consensus Estimate for earnings is pegged at $1.86 per share, indicating a year-over-year rise of 12%.For fiscal 2026, Amdocs expects revenues to grow in the 1.7-5.7% range. The on-GAAP operating margin is anticipated to be in the range of 21.3-21.9% for fiscal 2026. Non-GAAP earnings per share are expected to grow in the band of 4-8%. The Zacks Consensus Estimate for earnings is pegged at $7.60 per share, indicating a year-over-year rise of 8.9%. The company expects free cash flow between $710 million and $730 million.How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in fresh estimates.VGM ScoresCurrently, Amdocs has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. However, the stock has a score of B on the value side, putting it in the top 40% for value investors.Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. It's no surprise Amdocs has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.Performance of an Industry PlayerAmdocs belongs to the Zacks Computers - IT Services industry. Another stock from the same industry, CDW (CDW), has gained 1.5% over the past month. More than a month has passed since the company reported results for the quarter ended September 2025.CDW reported revenues of $5.74 billion in the last reported quarter, representing a year-over-year change of +4%. EPS of $2.71 for the same period compares with $2.63 a year ago.CDW is expected to post earnings of $2.43 per share for the current quarter, representing a year-over-year change of -2%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.6%.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for CDW. Also, the stock has a VGM Score of C.Free Report: Profiting from the 2nd Wave of AI ExplosionThe next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.Investors who bought shares like Nvidia at the right time have had a shot at huge gains.But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.Access AI Boom 2.0 now, absolutely free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amdocs Limited (DOX): Free Stock Analysis Report CDW Corporation (CDW): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Amdocs

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Amdocs

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Amdocs LtdShs

Wer­bung

Analysen zu Amdocs LtdShs

DatumRatingAnalyst
31.01.2018Amdocs BuyStifel, Nicolaus & Co., Inc.
12.11.2015Amdocs Equal WeightBarclays Capital
11.11.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
10.09.2015Amdocs OutperformOppenheimer & Co. Inc.
30.07.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
31.01.2018Amdocs BuyStifel, Nicolaus & Co., Inc.
11.11.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
10.09.2015Amdocs OutperformOppenheimer & Co. Inc.
30.07.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
19.03.2015Amdocs OutperformOppenheimer & Co. Inc.
DatumRatingAnalyst
12.11.2015Amdocs Equal WeightBarclays Capital
14.01.2011Amdocs neutralGoldman Sachs Group Inc.
22.07.2010Amdocs neutralWedbush Morgan Securities Inc.
19.07.2010Amdocs equal-weightBarclays Capital
23.04.2010Amdocs "hold"Kaufman Bros., LP
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Amdocs LtdShs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen